Therapeutic strategy targeting Jak3 for systemic lupus erythematosus
Project/Area Number |
21790953
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
膠原病・アレルギー・感染症内科学
|
Research Institution | University of Occupational and Environmental Health, Japan |
Principal Investigator |
HIRATA Shintaro University of Occupational and Environmental Health, Japan, 医学部, 助教 (90525461)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 膠原病学 / 全身性エリテマトーデス / JAK(Janus kinase) / CP690,550 / CD4陽性T細胞 / サイトカイン / JAK (Janus kinase) |
Research Abstract |
To investigate the effectiveness of Jak inhibition on systemic lupus erythematosus (SLE), CP690,550, a Jak3 specific inhibitor was utilized. CP690,550 strongly suppressed CD4+ T cell proliferation and production of IFN-・ and IL-17, induced by CD3 and CD28 stimuli, in a dose dependent manner. However, CP690,550 did not affect B cell proliferation, induced by BCR and sCD40L stimuli. Moreover, CP690,550 also suppressed mRNA expression of IFN-・ and IL-17 in a dose dependent manner, but did not induced CD4+ T cell apoptosis. Becasuse previous reports have pointed out the enhanced production of IFN-・ and IL-17 in SLE patient, our results indicate the possible effectiveness of Jak3 inhibition on SLE.
|
Report
(3 results)
Research Products
(10 results)
-
-
-
-
-
-
-
[Presentation] 当科におけるアダリムマブ24週投与の解析アダリムマブの効果予測の可能性2009
Author(s)
平田信太郎, 齋藤和義, 久保智史, 宮川一平, 福與俊介, 花見健太郎, 湯川宗之助, 岩田慈, 名和田雅夫, 辻村静代, 中野和久, 山岡邦宏, 田中良哉
Organizer
第38回九州リウマチ学会
Place of Presentation
久留米
Year and Date
2009-09-05
Related Report
-
-
-